First Laboratory of Pharmacology, School of Medicine, Campus of Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.
Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Curr Obes Rep. 2022 Sep;11(3):166-179. doi: 10.1007/s13679-022-00474-0. Epub 2022 May 2.
Obesity is closely associated with nonalcoholic fatty liver disease (NAFLD), a highly prevalent disease without any approved medication. The aim of this review was to summarize the evidence on the effect of anti-obesity medications on NAFLD, especially focusing on hepatic histology.
Orlistat and some glucagon-like peptide-1 receptor analogs, including liraglutide and semaglutide, have beneficial effects on hepatic steatosis and inflammation, but not fibrosis. Other anti-obesity medications, including lorcaserin, setmelanotide, phentermine hydrochloric, phentermine/topiramate, and naltrexone/bupropion, have been minimally investigated in NAFLD. Furthermore, medications like sodium-glucose cotransporter-2 inhibitors and farnesoid X receptor have shown beneficial effects in both NAFLD and obesity, but they have not been licensed for either disease. Liraglutide, semaglutide, and orlistat may be currently used in selected patients with obesity and NAFLD. Further research is warranted, since targeting obesity may provide additional benefits on its comorbidities, including NAFLD.
肥胖与非酒精性脂肪性肝病（NAFLD）密切相关，后者是一种患病率极高的疾病，但尚无获批的药物。本文旨在总结抗肥胖药物治疗 NAFLD 的疗效证据，特别关注肝组织学变化。
奥利司他和一些胰高血糖素样肽-1 受体类似物（包括利拉鲁肽和司美格鲁肽）对肝脂肪变性和炎症有益，但对纤维化无效。其他抗肥胖药物，如氯卡色林、司美格鲁肽、盐酸苯丙醇胺、盐酸苯丁胺/托吡酯和纳曲酮/安非他酮，在 NAFLD 中的研究较少。此外，钠-葡萄糖共转运蛋白-2 抑制剂和法尼醇 X 受体等药物对 NAFLD 和肥胖均有益，但尚未获批用于治疗这两种疾病。利拉鲁肽、司美格鲁肽和奥利司他可能适用于肥胖合并 NAFLD 的特定患者。由于针对肥胖症的治疗可能对其合并症（包括非酒精性脂肪性肝病）有额外获益，因此需要进一步研究。
